Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NEO

Neogenomics Inc

Dec 12 • 04:00PM ET

17.90

Dollar change -0.27
Percentage change -1.49	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN LH DGX BIO QGEN EXAS NVCR GH TMO A

| Held by: IJR IWM VTI VB VXF VBK IJT SPSM IWN SLYG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.62	Insider Own	1.20%	Shs Outstand	128.06M	Perf Week	4.13%
Market Cap	2.30B	Forward P/E	90.90	EPS next Y	0.20	Insider Trans	-0.40%	Shs Float	126.83M	Perf Month	9.61%
Income	-77.73M	PEG	-	EPS next Q	0.03	Inst Own	97.50%	Short Float	2.91%	Perf Quarter	9.15%
Sales	644.12M	P/S	3.57	EPS this Y	181.67%	Inst Trans	-2.42%	Short Ratio	4.90	Perf Half Y	33.38%
Book/sh	7.09	P/B	2.52	EPS next Y	100.94%	ROA	-4.68%	Short Interest	3.69M	Perf Year	-5.14%
Cash/sh	3.02	P/C	5.92	EPS next 5Y	-	ROE	-8.38%	52W Range	12.77 - 21.22	Perf YTD	10.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-5.93%	52W High	-15.65%	Beta	1.23
Dividend TTM	-	Quick Ratio	1.91	Sales past 5Y	17.35%	Gross Margin	40.57%	52W Low	40.17%	ATR (14)	0.66
Dividend Ex-Date	-	Current Ratio	1.99	EPS Y/Y TTM	20.06%	Oper. Margin	-13.37%	RSI (14)	62.90	Volatility	3.67% 3.81%
Employees	2100	Debt/Eq	0.67	Sales Y/Y TTM	12.06%	Profit Margin	-12.07%	Recom	1.53	Target Price	20.62
Option/Short	Yes / Yes	LT Debt/Eq	0.44	EPS Q/Q	5.36%	Payout	-	Rel Volume	0.79	Prev Close	18.17
Sales Surprise	0.49%	EPS Surprise	306.50%	Sales Q/Q	10.44%	Earnings	Nov 05 BMO	Avg Volume	752.68K	Price	17.90
SMA20	5.57%	SMA50	17.45%	SMA200	19.01%	Trades		Volume	596,347	Change	-1.49%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Initiated	Jefferies	Buy	$22
May-01-24	Resumed	Craig Hallum	Buy	$26
Dec-29-23	Reiterated	BTIG Research	Buy	$25 → $21
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight	$18
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy	$25
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy	$20
Feb-01-23	Upgrade	Needham	Hold → Buy	$15
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight	$13
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight	$34 → $16
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral	$25 → $18
Jan-18-22	Resumed	Stephens	Overweight	$40
Dec-16-21	Initiated	Cowen	Outperform	$42
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform	$53
Jun-03-21	Initiated	Goldman	Buy	$55
Feb-25-21	Resumed	Needham	Buy	$65
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Dec-11-24 08:05AM	NeoGenomics Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma (Business Wire)
Dec-09-24 08:10AM	NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting (Business Wire)
Dec-05-24 07:00AM	ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research (Business Wire)
Nov-19-24 08:15AM	NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment (Business Wire)
Nov-14-24 08:10AM	Felicia Williams Joins NeoGenomics Board of Directors (Business Wire)
07:00AM	Loading…
Nov-08-24 07:00AM	NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-06-24 12:00PM	NeoGenomics (NEO) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
02:24AM	Q3 2024 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents)
02:07AM	NeoGenomics Inc (NEO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Nov-05-24 10:00AM	NeoGenomics (NEO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) +5.59%
07:23AM	NeoGenomics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	NeoGenomics Reports Third Quarter 2024 Results (Business Wire)
Nov-04-24 09:55AM	Wall Street Analysts Believe NeoGenomics (NEO) Could Rally 51.29%: Here's is How to Trade (Zacks)
Oct-23-24 05:37AM	NeoGenomics gains conditional approval for solid tumour assays in New York (Medical Device Network)
Oct-22-24 08:10AM	NeoGenomics Receives New York State Approval for Neo Comprehensive Solid Tumor Test (Business Wire)
07:30AM	Loading…
Oct-15-24 07:30AM	NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024 (Business Wire)
Oct-08-24 09:55AM	NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:10AM	NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia (Business Wire)
Sep-23-24 06:47PM	NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation (Business Wire)
Sep-11-24 08:05AM	NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment (Business Wire)
Aug-29-24 08:05AM	NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Jul-29-24 06:00PM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q2 Earnings (Zacks) +17.96%
04:33PM	NeoGenomics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	NeoGenomics Reports Second Quarter 2024 Results (Business Wire)
Jul-20-24 08:09AM	Is NeoGenomics, Inc. (NEO) the Most Profitable Stock of the Last 20 Years? (Insider Monkey)
Jul-09-24 07:00AM	NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024 (Business Wire)
Jun-13-24 08:00AM	Fort Myers Mayor to Proclaim June as NeoGenomics Commitment to Cancer Month (Business Wire)
Jun-10-24 01:00AM	Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing (GlobeNewswire)
May-28-24 08:05AM	NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management (Business Wire)
May-02-24 02:14PM	NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.44%
03:04AM	Loading…
May-01-24 03:04AM	NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
Apr-30-24 11:53AM	NEO Stock Earnings: NeoGenomics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -8.54%
11:25AM	Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating (MT Newswires)
10:30AM	Here's What Key Metrics Tell Us About NeoGenomics (NEO) Q1 Earnings (Zacks)
08:52AM	NeoGenomics Q1 2024 Earnings: Revenue Surpasses Estimates, Net Loss Narrows (GuruFocus.com)
08:40AM	NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:37AM	NeoGenomics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	NeoGenomics Reports First Quarter 2024 Results (Business Wire)
Apr-23-24 10:00AM	NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks) +5.51%
Apr-18-24 07:05AM	NeoGenomics Announces Senior Leadership Promotions (Business Wire)
Apr-09-24 07:00AM	NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024 (Business Wire)
Mar-27-24 08:30AM	NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting (Business Wire)
Mar-20-24 12:00PM	All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy (Zacks) +5.57%
09:55AM	Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect? (Zacks)
07:00AM	NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report (Business Wire)
Mar-01-24 07:05AM	NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-29-24 08:12AM	Natera, Inc. (NASDAQ:NTRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:55AM	Wall Street Analysts Predict a 29.57% Upside in NeoGenomics (NEO): Here's What You Should Know (Zacks)
Feb-21-24 09:57AM	NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript (Insider Monkey) +12.11%
06:38AM	Q4 2023 Neogenomics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 07:00PM	NeoGenomics (NEO) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:35PM	NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:39PM	NeoGenomics Inc (NEO) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full Year 2023 (GuruFocus.com)
04:37PM	NeoGenomics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	NeoGenomics Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Feb-01-24 07:05AM	NeoGenomics Signs Working with Cancer Pledge in Support of Employees (Business Wire)
Jan-30-24 09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (GlobeNewswire) -5.61%
07:05AM	NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024 (Business Wire)
Jan-12-24 05:20AM	Bull of the Day: NeoGenomics (NEO) (Zacks)
Jan-02-24 07:05AM	NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-23 04:30PM	S&P 500 Misses Out On Record As Stock Market Fades Late; Small Caps On Pace For Record December (Investor's Business Daily) -18.10%
03:08PM	S&P 500 Near Record High As These 3 Dow Stocks Test Buy Points (Investor's Business Daily)
12:07PM	Altice USA, PENN Entertainment rise; Hess, NeoGenomics fall, Thursday, 12/28/2023 (Associated Press Finance)
08:10AM	NeoGenomics to Appeal Ruling (ACCESSWIRE)
Dec-05-23 08:00AM	NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response (ACCESSWIRE)
Nov-14-23 07:00AM	NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference (ACCESSWIRE) +8.71%
Nov-13-23 09:55AM	Wall Street Analysts See a 28.17% Upside in NeoGenomics (NEO): Can the Stock Really Move This High? (Zacks)
Nov-07-23 09:01AM	NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript (Insider Monkey) +14.20%
Nov-06-23 09:00PM	Compared to Estimates, NeoGenomics (NEO) Q3 Earnings: A Look at Key Metrics (Zacks)
06:10PM	NeoGenomics: Q3 Earnings Snapshot (Associated Press Finance)
04:33PM	NeoGenomics Inc (NEO) Reports 18% Revenue Increase in Q3 2023 (GuruFocus.com)
04:05PM	NeoGenomics Reports Third Quarter 2023 Results (ACCESSWIRE)
Nov-01-23 10:01AM	Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-23 09:55AM	Wall Street Analysts Think NeoGenomics (NEO) Could Surge 35.08%: Read This Before Placing a Bet (Zacks) -6.20%
Oct-24-23 07:00AM	NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios (ACCESSWIRE) +7.59%
05:20AM	Bull of the Day: NeoGenomics (NEO) (Zacks)
02:18AM	NeoGenomics and SolarEdge Technologies have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Oct-18-23 08:26AM	NeoGenomics (NEO) Soars 8.9%: Is Further Upside Left in the Stock? (Zacks)
Oct-17-23 09:20AM	NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023 (ACCESSWIRE) +8.85%
09:15AM	Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 (PR Newswire)
Oct-13-23 12:00PM	NeoGenomics (NEO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Aug-08-23 11:30AM	NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:22AM	NeoGenomics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	NeoGenomics Reports Second Quarter 2023 Results (ACCESSWIRE)
Jul-27-23 07:00AM	NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer (ACCESSWIRE) -5.67%
Jul-18-23 07:10AM	NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023 (ACCESSWIRE)
Jun-29-23 07:00AM	NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors (ACCESSWIRE)
Jun-21-23 08:00PM	NEO: Rating increased to a HOLD (Argus Research)
Jun-15-23 04:45PM	NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage (ACCESSWIRE)
Jun-08-23 01:36PM	Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking (Simply Wall St.)
Jun-06-23 08:02AM	The Proxies: A celebration of substantial corporate perks (Financial Times)
Jun-05-23 07:00AM	NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer (ACCESSWIRE) -7.73%
Jun-01-23 07:00AM	NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference (ACCESSWIRE)
May-30-23 07:00AM	NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO (ACCESSWIRE)
May-17-23 08:16AM	Zacks.com featured highlights include First Watch Restaurant, NeoGenomics and Universal Stainless & Alloy Products (Zacks)
May-16-23 06:59AM	3 Best Breakout Stocks to Invest in for Superlative Returns (Zacks) -6.48%
May-10-23 01:26AM	4 big analyst picks: Alcon upgraded to Outperform after Q1 beat \| Pro Recap (Investing.com) +7.67%
May-09-23 01:39PM	NeoGenomics Reports Q1 Topline Growth, Lifts Annual Guidance, Shares Soar (Benzinga) +18.51%

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Olivo Alicia C	General Counsel	Nov 15 '24	Sale	15.36	5,175	79,475	37,129	Nov 19 05:43 PM
ALICIA OLIVO	Officer	Nov 15 '24	Proposed Sale	15.79	5,175	81,713		Nov 15 04:35 PM
Olivo Alicia C	General Counsel	Aug 15 '24	Sale	16.05	1,040	16,695	43,813	Aug 19 04:17 PM
ALICIA OLIVO	Officer	Aug 15 '24	Proposed Sale	15.82	1,040	16,453		Aug 15 04:29 PM
BRUCE K CROWTHER	Officer	Aug 15 '24	Proposed Sale	15.95	8,353	133,243		Aug 15 04:12 PM
Zook Anthony P.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:40 PM
TETRAULT LYNN A.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	61,398	Aug 13 04:37 PM
Perez David Brian	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	21,636	Aug 13 04:34 PM
Kelly Michael Aaron	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	31,755	Aug 13 04:32 PM
KANOVSKY STEPHEN M	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	36,090	Aug 13 04:27 PM
HANNAH ALISON L.	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	118,769	Aug 13 04:24 PM
Gunn Neil	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:21 PM
Floegel Elizabeth	Director	Aug 10 '24	Option Exercise	0.00	11,336	0	11,336	Aug 13 04:17 PM
Olivo Alicia C	General Counsel	May 15 '24	Sale	15.74	1,049	16,511	44,867	May 17 04:07 PM
Smith Christopher M	Chief Executive Officer	May 11 '24	Option Exercise	0.00	96,126	0	679,432	May 14 09:39 PM
Olivo Alicia C	General Counsel	May 11 '24	Option Exercise	0.00	13,004	0	45,916	May 14 09:39 PM
Stone Warren	Chief Commerical Officer	May 11 '24	Option Exercise	0.00	19,224	0	100,658	May 14 09:38 PM
Sherman Jeffrey Scott	Chief Financial Officer	May 11 '24	Option Exercise	0.00	26,010	0	148,505	May 14 09:38 PM
Harris Melody	Chf Ops Off, Pres, Informatics	May 11 '24	Option Exercise	0.00	7,068	0	110,023	May 14 09:38 PM
TETRAULT LYNN A.	Director	Mar 04 '24	Sale	15.97	6,112	97,579	50,062	Mar 06 04:26 PM
Olivo Alicia C	General Counsel	Feb 15 '24	Sale	14.96	2,587	38,713	34,866	Feb 20 04:32 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NEO

Neogenomics Inc

Upgrade your FINVIZ experience